Development and characterization of a patient‑derived orthotopic xenograft of therapy‑resistant breast cancer

Butti,Ramesh; Kapse,Prachi; Bhadauriya,Garima; Ahmad,Suhail; Chaubal,Rohan; Parab,Pallavi; Kadam,Rasika; Mahapatra,Soumya S.; Shet,Tanuja; Dutt,Amit; Gupta,Sudeep; Kundu,Gopal C.

doi:10.3892/or.2023.8536

Development and characterization of a patient‑derived orthotopic xenograft of therapy‑resistant breast cancer

Authors:
- Ramesh Butti
- Prachi Kapse
- Garima Bhadauriya
- Suhail Ahmad
- Rohan Chaubal
- Pallavi Parab
- Rasika Kadam
- Soumya S. Mahapatra
- Tanuja Shet
- Amit Dutt
- Sudeep Gupta
- Gopal C. Kundu
View Affiliations

Affiliations: Laboratory of Tumor Biology, Angiogenesis and Nanomedicine Research, National Centre for Cell Science, Pune, Maharashtra 411007, India, Integrated Cancer Genomics Laboratory, Tata Memorial Centre‑Advanced Centre for Treatment, Research and Education in Cancer (TMC‑ACTREC), Navi Mumbai, Maharashtra 410210, India, Homi Bhabha National Institute, Training School Complex, Mumbai 400094, India, Clinical Genomics and Hypoxia Lab (Clinician Scientist Lab), TMC‑ACTREC, Navi Mumbai, Maharashtra 410210, India, School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT) Deemed to be University, Bhubaneswar, Odisha 751024, India
Published online on: March 27, 2023 https://doi.org/10.3892/or.2023.8536
Article Number: 99
Copyright: © Butti et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Numerous years of cell line‑based studies have enhanced the current understanding of cancer and its treatment. However, limited success has been achieved in treating hormone receptor‑positive, HER2‑negative metastatic breast cancers that are refractory to treatment. The majority of cancer cell lines are unsuitable for use as pre‑clinical models that mimic this critical and often fatal clinical type, since they are derived from treatment‑naive or non‑metastatic breast cancer cases. The aim of the present study was to develop and characterize patient‑derived orthotopic xenografts (PDOXs) from patients with endocrine hormone receptor‑positive, HER2‑negative metastatic breast cancer who had relapsed on therapy. A patient who progressed on endocrine hormone therapy provided her tumor via a biobank. This tumor was implanted in mice. It was then serially passaged by implanting PDOX tumor fragments into another set of mice to develop further generations of PDOXs. These tissues were characterized using various histological and biochemical techniques. Histological, immunofluorescence and western blot analyses indicated that the PDOX tumors retained a similar morphology, histology and subtype‑specific molecular features to that of the patient's tumor. The present study successfully established PDOXs of hormone‑resistant breast cancer and characterized them in comparison with those derived from the original breast cancer tissue of the patient. The data highlight the reliability and usefulness of PDOX models for studies of biomarker discovery and preclinical drug screening. The present study was registered with the clinical trial registry of India (CTRI; registration no. CTRI/2017/11/010553; registered on 17/11/2017).

View Figures

View References

1	Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan KL, Santhappan S, Nallasamy V, John A, Narasimhan S and Roselind FS: ICMR-NCDIR-NCRP Investigator Group: Cancer statistics, 2020: Report from national cancer registry programme, India. JCO Glob Oncol. 6:1063–1075. 2020. View Article : Google Scholar : PubMed/NCBI
2	Malvia S, Bagadi SA, Dubey US and Saxena S: Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol. 13:289–295. 2017. View Article : Google Scholar : PubMed/NCBI
3	Mehrotra R and Yadav K: Breast cancer in India: Present scenario and the challenges ahead. World J Clin Oncol. 13:209–218. 2022. View Article : Google Scholar : PubMed/NCBI
4	Chakraborty S and Rahman T: The difficulties in cancer treatment. Ecancermedicalscience. 6:ed162012.PubMed/NCBI
5	Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA and Eckhardt SG: Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 9:338–350. 2012. View Article : Google Scholar : PubMed/NCBI
6	Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, et al: Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci USA. 108:18708–18713. 2011. View Article : Google Scholar : PubMed/NCBI
7	Burdall SE, Hanby AM, Lansdown MR and Speirs V: Breast cancer cell lines: Friend or foe? Breast Cancer Res. 5:89–95. 2003. View Article : Google Scholar : PubMed/NCBI
8	Cifani P, Kirik U, Waldemarson S and James P: Molecular portrait of breast-cancer-derived cell lines reveals poor similarity with tumors. J Proteome Res. 14:2819–2827. 2015. View Article : Google Scholar : PubMed/NCBI
9	Manning HC, Buck JR and Cook RS: Mouse models of breast cancer: Platforms for discovering precision imaging diagnostics and future cancer medicine. J Nucl Med. 57 (Suppl 1):60S–68S. 2016. View Article : Google Scholar : PubMed/NCBI
10	Guo S, Qian W, Cai J, Zhang L, Wery JP and Li QX: Molecular pathology of patient tumors, patient-derived xenografts, and cancer cell lines. Cancer Res. 76:4619–4626. 2016. View Article : Google Scholar : PubMed/NCBI
11	Braekeveldt N, von Stedingk K, Fransson S, Martinez-Monleon A, Lindgren D, Axelson H, Levander F, Willforss J, Hansson K, Øra I, et al: Patient-derived xenograft models reveal intratumor heterogeneity and temporal stability in neuroblastoma. Cancer Res. 78:5958–5969. 2018. View Article : Google Scholar : PubMed/NCBI
12	Matossian MD, Burks HE, Bowles AC, Elliott S, Hoang VT, Sabol RA, Pashos NC, O'Donnell B, Miller KS, Wahba BM, et al: A novel patient-derived xenograft model for claudin-low triple-negative breast cancer. Breast Cancer Res Treat. 169:381–390. 2018. View Article : Google Scholar : PubMed/NCBI
13	Ramani VC, Lemaire CA, Triboulet M, Casey KM, Heirich K, Renier C, Vilches-Moure JG, Gupta R, Razmara AM, Zhang H, et al: Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer. Breast Cancer Res. 21:982019. View Article : Google Scholar : PubMed/NCBI
14	Pandrangi SL, Raju Bagadi SA, Sinha NK, Kumar M, Dada R, Lakhanpal M, Soni A, Malvia S, Simon S, Chintamani C, et al: Establishment and characterization of two primary breast cancer cell lines from young Indian breast cancer patients: Mutation analysis. Cancer Cell Int. 14:142014. View Article : Google Scholar : PubMed/NCBI
15	Chakraborty G, Jain S and Kundu GC: Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 68:152–161. 2008. View Article : Google Scholar : PubMed/NCBI
16	Bhimani J, Ball K and Stebbing J: Patient-derived xenograft models-the future of personalised cancer treatment. Br J Cancer. 122:601–602. 2020. View Article : Google Scholar : PubMed/NCBI
17	Okada S, Vaeteewoottacharn K and Kariya R: Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) models. Cells. 8:8892019. View Article : Google Scholar : PubMed/NCBI
18	Kessous R, Wissing MD, Laskov I, Abitbol J, Bitharas J, Agnihotram VR, Yasmeen A, Salvador S, Lau S and Gotlieb WH: Multiple lines of chemotherapy for patients with high-grade ovarian cancer: Predictors for response and effect on survival. Int J Cancer. 148:2304–2312. 2021. View Article : Google Scholar : PubMed/NCBI
19	Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, Ray-Coquard I, Sehouli J, Harter P and du Bois A: AGO and GINECO study group: The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 23:2605–2612. 2012. View Article : Google Scholar : PubMed/NCBI
20	Park IH, Lee KS and Ro J: Effects of second and subsequent lines of chemotherapy for metastatic breast cancer. Clin Breast Cancer. 15:e55–e62. 2015. View Article : Google Scholar : PubMed/NCBI
21	Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, McKenna S, Mobraaten L, Rajan TV, Greiner DL, et al: Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol. 154:180–191. 1995. View Article : Google Scholar : PubMed/NCBI
22	Chijiwa T, Kawai K, Noguchi A, Sato H, Hayashi A, Cho H, Shiozawa M, Kishida T, Morinaga S, Yokose T, et al: Establishment of patient-derived cancer xenografts in immunodeficient NOG mice. Int J Oncol. 47:61–70. 2015. View Article : Google Scholar : PubMed/NCBI
23	Shultz LD, Goodwin N, Ishikawa F, Hosur V, Lyons BL and Greiner DL: Human cancer growth and therapy in immunodeficient mouse models. Cold Spring Harb Protoc. 2014:694–708. 2014. View Article : Google Scholar : PubMed/NCBI
24	Brown KM, Xue A, Mittal A, Samra JS, Smith R and Hugh TJ: Patient-derived xenograft models of colorectal cancer in pre-clinical research: A systematic review. Oncotarget. 7:66212–66225. 2016. View Article : Google Scholar : PubMed/NCBI
25	Mosier DE, Stell KL, Gulizia RJ, Torbett BE and Gilmore GL: Homozygous scid/scid; beige/beige mice have low levels of spontaneous or neonatal T cell-induced B cell generation. J Exp Med. 177:191–194. 1993. View Article : Google Scholar : PubMed/NCBI
26	Chen L, Pan X, Zhang YH, Hu X, Feng K, Huang T and Cai YD: Primary tumor site specificity is preserved in patient-derived tumor xenograft models. Front Genet. 10:7382019. View Article : Google Scholar : PubMed/NCBI